Approaches in metabolomics for regulatory toxicology applications

被引:27
|
作者
Olesti, Eulalia [1 ,2 ,3 ]
Gonzalez-Ruiz, Victor [1 ,2 ,3 ]
Wilks, Martin F. [3 ,4 ]
Boccard, Julien [1 ,2 ,3 ]
Rudaz, Serge [1 ,2 ,3 ]
机构
[1] Univ Geneva, Sch Pharmaceut Sci, Geneva, Switzerland
[2] Univ Geneva, Inst Pharmaceut Sci Western Switzerland, Geneva, Switzerland
[3] Swiss Ctr Appl Human Toxicol SCAHT, Basel, Switzerland
[4] Univ Basel, Dept Pharmaceut Sci, Basel, Switzerland
基金
瑞士国家科学基金会;
关键词
ADVERSE OUTCOME PATHWAYS; APPLYING OMICS TECHNOLOGIES; MS-BASED METABOLOMICS; RISK-ASSESSMENT; LC-MS; MULTIVARIATE-ANALYSIS; EMERGING APPLICATIONS; CONCEPTUAL-FRAMEWORK; EXPERIMENTAL-DESIGN; MASS-SPECTROMETRY;
D O I
10.1039/d0an02212h
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Innovative methodological approaches are needed to conduct human health and environmental risk assessments on a growing number of marketed chemicals. Metabolomics is progressively proving its value as an efficient strategy to perform toxicological evaluations of new and existing substances, and it will likely become a key tool to accelerate chemical risk assessments. However, additional guidance with widely accepted and harmonized procedures is needed before metabolomics can be routinely incorporated in decision-making for regulatory purposes. The aim of this review is to provide an overview of metabolomic strategies that have been successfully employed in toxicity assessment as well as the most promising workflows in a regulatory context. First, we provide a general view of the different steps of regulatory toxicology-oriented metabolomics. Emphasis is put on three key elements: robustness of experimental design, choice of analytical platform, and use of adapted data treatment tools. Then, examples in which metabolomics supported regulatory toxicology outputs in different scenarios are reviewed, including chemical grouping, elucidation of mechanisms of toxicity, and determination of points of departure. The overall intention is to provide insights into why and how to plan and conduct metabolomic studies for regulatory toxicology purposes.
引用
收藏
页码:1820 / 1834
页数:15
相关论文
共 50 条
  • [1] Metabolomics in Toxicology: Preclinical and Clinical Applications
    Robertson, Donald G.
    Watkins, Paul B.
    Reily, Michael D.
    TOXICOLOGICAL SCIENCES, 2011, 120 : S146 - S170
  • [3] Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology
    Heijne, Wilbert H. M.
    Kienhuis, Anne S.
    van Ommen, Ben
    Stierum, Rob H.
    Groten, John P.
    EXPERT REVIEW OF PROTEOMICS, 2005, 2 (05) : 767 - 780
  • [4] Applications of population approaches in toxicology
    Bois, FY
    TOXICOLOGY LETTERS, 2001, 120 (1-3) : 385 - 394
  • [5] Applications of Metabolomics in Forensic Toxicology and Forensic Medicine
    Szeremeta, Michal
    Pietrowska, Karolina
    Niemcunowicz-Janica, Anna
    Kretowski, Adam
    Ciborowski, Michal
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (06) : 1 - 16
  • [6] Metabolomics: Concepts and applications in biological and forensic toxicology
    Lenski, Marie
    Brunoc, Clement
    Darrouzain, Francois
    Allorge, Delphine
    TOXICOLOGIE ANALYTIQUE ET CLINIQUE, 2023, 35 (02) : 96 - 112
  • [7] Use cases, best practice and reporting standards for metabolomics in regulatory toxicology
    Viant, Mark R.
    Ebbels, Timothy M. D.
    Beger, Richard D.
    Ekman, Drew R.
    Epps, David J. T.
    Kamp, Hennicke
    Leonards, Pim E. G.
    Loizou, George D.
    MacRae, James I.
    van Ravenzwaay, Bennard
    Rocca-Serra, Philippe
    Salek, Reza M.
    Walk, Tilmann
    Weber, Ralf J. M.
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [8] Use cases, best practice and reporting standards for metabolomics in regulatory toxicology
    Mark R. Viant
    Timothy M. D. Ebbels
    Richard D. Beger
    Drew R. Ekman
    David J. T. Epps
    Hennicke Kamp
    Pim E. G. Leonards
    George D. Loizou
    James I. MacRae
    Bennard van Ravenzwaay
    Philippe Rocca-Serra
    Reza M. Salek
    Tilmann Walk
    Ralf J. M. Weber
    Nature Communications, 10
  • [9] The sensitivity of metabolomics versus classical regulatory toxicology from a NOAEL perspective
    van Ravenzwaay, B.
    Montoya, G. A.
    Fabian, E.
    Herold, M.
    Krennrich, G.
    Looser, R.
    Mellert, W.
    Peter, E.
    Strauss, V.
    Walk, T.
    Kamp, H.
    TOXICOLOGY LETTERS, 2014, 227 (01) : 20 - 28
  • [10] Progress towards an OECD reporting framework for transcriptomics and metabolomics in regulatory toxicology
    Harrill, Joshua A.
    Viant, Mark R.
    Yauk, Carole L.
    Sachana, Magdalini
    Gant, Timothy W.
    Auerbach, Scott S.
    Beger, Richard D.
    Bouhifd, Mounir
    O'Brien, Jason
    Burgoon, Lyle
    Caiment, Florian
    Carpi, Donatella
    Chen, Tao
    Chorley, Brian N.
    Colbourne, John
    Corvi, Raffaella
    Debrauwer, Laurent
    O'Donovan, Claire
    Ebbels, Timothy M. D.
    Ekman, Drew R.
    Faulhammer, Frank
    Gribaldo, Laura
    Hilton, Gina M.
    Jones, Stephanie P.
    Kende, Aniko
    Lawson, Thomas N.
    Leite, Sofia B.
    Leonards, Pim E. G.
    Luijten, Mirjam
    Martin, Alberto
    Moussa, Laura
    Rudaz, Serge
    Schmitz, Oliver
    Sobanski, Tomasz
    Strauss, Volker
    Vaccari, Monica
    Vijay, Vikrant
    Weber, Ralf J. M.
    Williams, Antony J.
    Williams, Andrew
    Thomas, Russell S.
    Whelan, Maurice
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2021, 125